Aliases & Classifications for Melanoma

Aliases & Descriptions for Melanoma:

Name: Melanoma 12 29 52 41 42 14 69
Malignant Melanoma 12 29 14
Cutaneous Melanoma 69
Naevocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1909
MeSH 42 D008545
NCIt 47 C3224
ICD10 33 D03.9
UMLS 69 C0025202

Summaries for Melanoma

MedlinePlus : 41 melanoma is the most serious type of skin cancer. often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. most melanomas have a black or black-blue area. melanoma may also appear as a new mole. it may be black, abnormal, or "ugly looking." thinking of "abcde" can help you remember what to watch for: asymmetry - the shape of one half does not match the other border - the edges are ragged, blurred or irregular color - the color is uneven and may include shades of black, brown and tan diameter - there is a change in size, usually an increase evolving - the mole has changed over the past few weeks or months surgery is the first treatment of all stages of melanoma. other treatments include chemotherapy and radiation, biologic, and targeted therapies. biologic therapy boosts your body's own ability to fight cancer. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

MalaCards based summary : Melanoma, also known as malignant melanoma, is related to mediastinitis and aortic aneurysm, and has symptoms including exanthema and pruritus. An important gene associated with Melanoma is MAGEA4 (MAGE Family Member A4), and among its related pathways/superpathways are Melanoma and Glioblastoma Multiforme. The drugs Erivedge and Intron A have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and lymph node, and related phenotype is pigmentation.

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from melanocytes which are found in skin, the bowel and the eye.

Novus Biologicals : 53 Melanoma is a malignant tumor that results from uncontrolled growth of pigmented cells, called melanocytes. Several types of melanoma exist, including superficial spreading melanoma, nodular melanoma and lentigo melanoma. Melanoma diagnosis is traditionally supported by the presence of the S-100 protein marker and HMB-45, however research has determined the sensitivity and specificity of three novel antibodies as markers for melanoma: Mitf, Melan-A and tyrosinase.

Wikipedia : 71 Melanoma, also known as malignant melanoma, is a type of cancer that develops from the... more...

Related Diseases for Melanoma

Diseases related to Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 652)
id Related Disease Score Top Affiliating Genes
1 mediastinitis 29.4 MITF MLANA
2 aortic aneurysm 29.4 CDK4 CDKN2A MLANA
3 malignant melanoma, somatic 12.2
4 acral lentiginous melanoma 12.2
5 uveal melanoma 12.2
6 ocular melanoma 12.2
7 skin melanoma 12.2
8 nodular malignant melanoma 12.1
9 amelanotic melanoma 12.1
10 mucosal melanoma 12.1
11 lentigo maligna melanoma 12.1
12 digestive system melanoma 12.0
13 melanoma-associated retinopathy 12.0
14 superficial spreading melanoma 12.0
15 melanoma and neural system tumor syndrome 12.0
16 pancreatic cancer/melanoma syndrome 12.0
17 melanoma, cutaneous malignant 8 12.0
18 melanoma, cutaneous malignant, 6 12.0
19 melanoma, cutaneous malignant, 9 12.0
20 melanoma, cutaneous malignant, 3 12.0
21 melanoma, cutaneous malignant, 2 12.0
22 melanoma, cutaneous malignant, 5 12.0
23 malignant spindle cell melanoma 12.0
24 dysplastic nevus syndrome 11.9
25 choroid spindle cell melanoma 11.9
26 melanoma of soft tissue 11.9
27 iris spindle cell melanoma 11.9
28 posterior uveal melanoma 11.9
29 ciliary body spindle cell melanoma 11.9
30 melanoma, cutaneous malignant 10 11.8
31 malignant conjunctival melanoma 11.8
32 vulvar melanoma 11.8
33 meningeal melanoma 11.8
34 spinal cord melanoma 11.8
35 gallbladder melanoma 11.8
36 malignant iris melanoma 11.8
37 epithelioid cell melanoma 11.8
38 malignant choroid melanoma 11.8
39 primary malignant melanoma of the cervix 11.8
40 balloon cell malignant melanoma 11.8
41 orbital melanoma 11.7
42 melanoma metastasis 11.7
43 ovarian melanoma 11.7
44 necrotic uveal melanoma 11.7
45 malignant eyelid melanoma 11.7
46 primary melanoma of the central nervous system 11.7
47 malignant anus melanoma 11.7
48 cervix melanoma 11.7
49 malignant cornea melanoma 11.7
50 mixed cell uveal melanoma 11.7

Graphical network of the top 20 diseases related to Melanoma:



Diseases related to Melanoma

Symptoms & Phenotypes for Melanoma

UMLS symptoms related to Melanoma:


exanthema, pruritus

MGI Mouse Phenotypes related to Melanoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 pigmentation MP:0001186 9.1 BRAF CDK4 CDKN2A GPNMB MITF MLANA

Drugs & Therapeutics for Melanoma

FDA approved drugs:

(show all 11)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Erivedge 17 46 VISMODEGIB Genentech Approved January 2012
2
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
3
Keytruda 17 46 PEMBROLIZUMAB Merck Approved September 2014
4
Mekinist 17 46 TRAMETINIB DIMETHYL SULFOXIDE GlaxoSmithKline Approved May of 2013
5
Odomzo 17 46 SONIDEGIB PHOSPHATE Novartis Jul-15
6
Opdivo 17 46 NIVOLUMAB Bristol-Myers Squibb Approved March 2015/ Approved December 2014, Approved March 2015
7
Proleukin 17 46 ALDESLEUKIN Chiron Approved January 1998
8
Sylatron 17 46 PEGINTERFERON ALFA-2B Merck Approved April 2011
9
Tafinlar 17 46 DABRAFENIB MESYLATE GlaxoSmithKline Approved May 2013
10
Yervoy 17 46 IPILIMUMAB Bristol-Myers Squibb Approved March 2011
11
Zelboraf 17 46 VEMURAFENIB Roche Approved August of 2011

Drugs for Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 610)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
3
Vindesine Approved Phase 4 59917-39-4, 53643-48-4 40839
4
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
5
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99011-02-6 57469
6
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 124-94-7 31307
7
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
8
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
10
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
11
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
12
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
13
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
14
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 85898-30-2, 110942-02-4
15
Etanercept Approved, Investigational Phase 4 185243-69-0
16
Citalopram Approved Phase 4 59729-33-8 2771
17
nivolumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 946414-94-4
18
Aminolevulinic acid Approved Phase 4,Phase 2 106-60-5 137
19
Somatostatin Approved Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
20
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
21
Bortezomib Approved, Investigational Phase 4,Phase 2,Phase 1 179324-69-7 387447 93860
22
Olaparib Approved Phase 4,Phase 1 763113-22-0 23725625
23
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
24
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
25
Technetium tc 99m sulfur colloid Approved Phase 4,Early Phase 1
26
Ceritinib Approved Phase 4,Phase 2,Early Phase 1 1032900-25-6
27
Crizotinib Approved Phase 4,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
28
Palbociclib Approved Phase 4,Phase 1,Phase 2 571190-30-2 11431660 5005498 5330286
29
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
30
Lapatinib Approved March 2007, Investigational Phase 4,Phase 2 231277-92-2, 388082-78-8 208908 9941095
31 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
33 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
34 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
35 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1
38 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 1,Phase 2
39 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
40 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
41 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
42 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Interleukin-2 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1
47 interferons Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2179)
id Name Status NCT ID Phase
1 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4
2 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4
3 Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma Completed NCT01253759 Phase 4
4 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4
5 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4
6 Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment Completed NCT00352885 Phase 4
7 A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection Completed NCT02476357 Phase 4
8 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
9 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4
10 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Recruiting NCT02626065 Phase 4
11 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4
12 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Recruiting NCT02685592 Phase 4
13 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
14 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Active, not recruiting NCT01515189 Phase 4
15 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4
16 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4
17 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4
18 Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer Active, not recruiting NCT02287675 Phase 4
19 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4
20 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4
21 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4
22 Assessment and Tracking of Long-term Alefacept Safety Terminated NCT00454701 Phase 4
23 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
24 Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients Unknown status NCT01861938 Phase 2, Phase 3
25 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3
26 Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma Unknown status NCT00002767 Phase 3
27 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
28 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3
29 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3
30 Vaccine Therapy for Patients With Stage III Melanoma Unknown status NCT00052130 Phase 3
31 Vaccine Therapy for Patients With Stage IV Melanoma Unknown status NCT00052156 Phase 3
32 Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma Unknown status NCT00002455 Phase 3
33 Treatment Of Radiation Retinopathy Trial Unknown status NCT00811200 Phase 2, Phase 3
34 Collaborative Ocular Melanoma Study (COMS) Unknown status NCT00000124 Phase 3
35 Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC Unknown status NCT00779714 Phase 3
36 Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon Unknown status NCT00226408 Phase 3
37 Treatment of Port Wine Stains in Children With Pulsed Dye Laser and Timolol Gel Unknown status NCT01272609 Phase 3
38 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology Unknown status NCT00207298 Phase 3
39 MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma Completed NCT00094653 Phase 3
40 Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma Completed NCT00002882 Phase 3
41 Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267) Completed NCT00091572 Phase 3
42 Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma Completed NCT00072124 Phase 3
43 Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma Completed NCT00003027 Phase 3
44 S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma Completed NCT00006237 Phase 3
45 Nordic Adjuvant IFN Melanoma Trial Completed NCT01259934 Phase 3
46 Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma Completed NCT00039000 Phase 3
47 Multicenter Selective Lymphadenectomy Trial (MSLT) Completed NCT00275496 Phase 3
48 Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma Completed NCT00002892 Phase 3
49 Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma Completed NCT00324155 Phase 3
50 Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB Completed NCT00204529 Phase 3

Search NIH Clinical Center for Melanoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: melanoma

Genetic Tests for Melanoma

Genetic tests related to Melanoma:

id Genetic test Affiliating Genes
1 Malignant Melanoma 29
2 Melanoma 29

Anatomical Context for Melanoma

MalaCards organs/tissues related to Melanoma:

39
Skin, T Cells, Lymph Node, Endothelial, Lung, Eye, Testes

Publications for Melanoma

Articles related to Melanoma:

(show top 50) (show all 11859)
id Title Authors Year
1
Melanomas and Dysplastic Nevi Differ in Epidermal CD1c+ Dendritic Cell Count. ( 28331853 )
2017
2
Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands. ( 27911126 )
2017
3
Expression of PIWIL3 in primary and metastatic melanoma. ( 27858163 )
2017
4
Recent Advances in Melanoma and Melanocyte Biology. ( 28089201 )
2017
5
The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology. ( 28263292 )
2017
6
Differential BMI1, TWIST1, SNAI2 mRNA expression pattern correlation with malignancy type in a spectrum of common cutaneous malignancies: basal cell carcinoma, squamous cell carcinoma, and melanoma. ( 27718152 )
2017
7
Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies. ( 28091975 )
2017
8
Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. ( 28092667 )
2017
9
WNT/I^-catenin signaling regulates mitochondrial activity to alter the oncogenic potential of melanoma in a PTEN-dependent manner. ( 28092677 )
2017
10
PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma. ( 28092671 )
2017
11
Comparative study on driver mutations in primary and metastatic melanomas at a single Japanese institute: A clue for intra- and inter-tumor heterogeneity. ( 27771229 )
2017
12
PD-1 Antibody-induced Guillain-BarrAc Syndrome in a Patient with Metastatic Melanoma. ( 27868138 )
2017
13
Reduced expression of the ATP2A2 gene in vemurafenib-induced keratoacanthoma-like papules in a melanoma patient. ( 27805257 )
2017
14
Familial Melanoma Associated with Li-Fraumeni Syndrome and Atypical Mole Syndrome: Total-body Digital Photography, Dermoscopy and Confocal Microscopy. ( 28218344 )
2017
15
Mutational Status of NRAS and BRAF Genes and Protein Expression Analysis in a Series of Primary Oral Mucosal Melanoma. ( 28134726 )
2017
16
Seasonality of birth for skin melanoma deserves further investigation. ( 28338933 )
2017
17
IRF4 rs12203592 functional variant and melanoma survival. ( 28103633 )
2017
18
Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma. ( 28407116 )
2017
19
Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus. ( 28042780 )
2017
20
Li-Fraumeni syndrome presenting as mucosal melanoma: Case report and treatment considerations. ( 27726232 )
2017
21
Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma. ( 28092675 )
2017
22
Do polychlorinated biphenyls cause cancer? A systematic review and meta-analysis of epidemiological studies on risk of cutaneous melanoma and non-Hodgkin lymphoma. ( 28535466 )
2017
23
Recall radiation myelitis after stereotactic radiation and dabrafenib in metastatic melanoma. ( 27830981 )
2017
24
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. ( 28056206 )
2017
25
Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. ( 27147251 )
2017
26
Health and Economic Burden of Skin Melanoma in Croatia - Cost-of-illness Study. ( 28511743 )
2017
27
NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF. ( 28119061 )
2017
28
Ethical dilemma in missed melanoma: What to tell the patient and other providers. ( 28089006 )
2017
29
External ear melanoma: A 10 year assessment of management and outcomes. ( 28089287 )
2017
30
Long noncoding RNA MHENCR promotes melanoma progression via regulating miR-425/489-mediated PI3K-Akt pathway. ( 28123636 )
2017
31
Long Noncoding RNA PVT1 as a Novel Diagnostic Biomarker and Therapeutic Target for Melanoma. ( 28265576 )
2017
32
ZIC5 Drives Melanoma Aggressiveness by PDGFD-Mediated Activation of FAK and STAT3. ( 27671679 )
2017
33
Capn4 promotes epithelial-mesenchymal transition in human melanoma cells through activation of the Wnt/I^-catenin pathway. ( 27878263 )
2017
34
U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab. ( 28087644 )
2017
35
NFa89I_B inhibition is associated with OPN/MMPa899 downregulation in cutaneous melanoma. ( 28075446 )
2017
36
Mouse models of UV-induced melanoma: genetics, pathology, and clinical relevance. ( 28092363 )
2017
37
The Long Non-Coding RNA RHPN1-AS1 Promotes Uveal Melanoma Progression. ( 28124977 )
2017
38
Prognostic value of apoptosis inducing factor in uveal melanoma. ( 28043154 )
2017
39
Comment on "Milham & Stetzer (2016) Tumor-specific frequencies and ocular melanoma." Electromag Biol Med http://dx.doi.org/10.1080/15368378.2016.1234390. ( 27715332 )
2017
40
Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. ( 27792058 )
2017
41
Parallel globules on the ridges caused by transepidermal elimination of melanocytic nests: A new dermoscopic pattern of acral melanoma. ( 28087014 )
2017
42
Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients. ( 27990595 )
2017
43
Invasive Melanoma in a Patient with Congenital Ichthyosiform Erythroderma. ( 27813222 )
2017
44
Tectona grandis leaf extract, free and associated with nanoemulsions, as a possible photosensitizer of mouse melanoma B16 cell. ( 28088105 )
2017
45
Metallic copper nanoparticle induces apoptosis in human skin melanoma, A-375 cell line. ( 28067213 )
2017
46
Prognostic Implications of the Largest Basal Tumor Diameter vs the TNM Staging System in Association With the Gene Expression Profile for Uveal Melanoma. ( 28056132 )
2017
47
KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. ( 28074351 )
2017
48
ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation. ( 28035401 )
2017
49
Immunotherapy of Uveal Melanoma: Vaccination Against Cancer. ( 27987156 )
2017
50
Ocular oncology: advances in retinoblastoma, uveal melanoma and conjunctival melanoma. ( 28069617 )
2017

Variations for Melanoma

ClinVar genetic disease variations for Melanoma:

6 (show top 50) (show all 107)
id Gene Variation Type Significance SNP ID Assembly Location
1 STK11 NM_000455.4(STK11): c.580G> T (p.Asp194Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913315 GRCh37 Chromosome 19, 1220487: 1220487
2 PTEN NM_000314.6(PTEN): c.633C> A (p.Cys211Ter) single nucleotide variant Pathogenic rs121909232 GRCh37 Chromosome 10, 89712015: 89712015
3 PTEN NM_000314.6(PTEN): c.55G> A (p.Asp19Asn) single nucleotide variant Pathogenic rs121909233 GRCh37 Chromosome 10, 89624281: 89624281
4 PTEN NM_000314.6(PTEN): c.649G> A (p.Val217Ile) single nucleotide variant Pathogenic rs121909234 GRCh37 Chromosome 10, 89717624: 89717624
5 HRAS NM_005343.3(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
6 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
7 KIT NM_000222.2(KIT): c.1676T> A (p.Val559Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913517 GRCh37 Chromosome 4, 55593610: 55593610
8 KIT NM_000222.2(KIT): c.1675_1677delGTT (p.Val560del) deletion Pathogenic/Likely pathogenic rs121913685 GRCh37 Chromosome 4, 55593609: 55593611
9 KIT NM_000222.2(KIT): c.2446G> T (p.Asp816Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
10 KIT NM_000222.2(KIT): c.2446G> C (p.Asp816His) single nucleotide variant Pathogenic/Likely pathogenic rs121913506 GRCh37 Chromosome 4, 55599320: 55599320
11 KIT NM_000222.2(KIT): c.1676T> C (p.Val559Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913517 GRCh37 Chromosome 4, 55593610: 55593610
12 KIT NM_000222.2(KIT): c.1924A> G (p.Lys642Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913512 GRCh37 Chromosome 4, 55594221: 55594221
13 NRAS NM_002524.4(NRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
14 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
15 NRAS NM_002524.4(NRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121434596 GRCh37 Chromosome 1, 115258744: 115258744
16 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic/Likely pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
17 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
18 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
19 BRAF NM_004333.4(BRAF): c.1789C> G (p.Leu597Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913369 GRCh37 Chromosome 7, 140453146: 140453146
20 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
21 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
22 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
23 CTNNB1 NM_001904.3(CTNNB1): c.95A> G (p.Asp32Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913396 GRCh37 Chromosome 3, 41266098: 41266098
24 CTNNB1 NM_001904.3(CTNNB1): c.110C> T (p.Ser37Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
25 CTNNB1 NM_001904.3(CTNNB1): c.134C> T (p.Ser45Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913409 GRCh37 Chromosome 3, 41266137: 41266137
26 CTNNB1 NM_001904.3(CTNNB1): c.133T> C (p.Ser45Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913407 GRCh37 Chromosome 3, 41266136: 41266136
27 NRAS NM_002524.4(NRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
28 BRAF NM_004333.4(BRAF): c.1796C> T (p.Thr599Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913375 GRCh37 Chromosome 7, 140453139: 140453139
29 BRAF NM_004333.4(BRAF): c.1799T> G (p.Val600Gly) single nucleotide variant Pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
30 NRAS NM_002524.4(NRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
31 NRAS NM_002524.4(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
32 NRAS NM_002524.4(NRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh37 Chromosome 1, 115258747: 115258747
33 NRAS NM_002524.4(NRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs121434595 GRCh37 Chromosome 1, 115258745: 115258745
34 RAF1 NM_002880.3(RAF1): c.769T> C (p.Ser257Pro) single nucleotide variant Pathogenic/Likely pathogenic rs727505017 GRCh37 Chromosome 3, 12645700: 12645700
35 MAP2K1 NM_002755.3(MAP2K1): c.371C> T (p.Pro124Leu) single nucleotide variant Pathogenic/Likely pathogenic rs397516792 GRCh37 Chromosome 15, 66729163: 66729163
36 MAP2K1 NM_002755.3(MAP2K1): c.199G> A (p.Asp67Asn) single nucleotide variant Pathogenic/Likely pathogenic rs727504317 GRCh37 Chromosome 15, 66727483: 66727483
37 FBN1 NM_000138.4(FBN1): c.5788+5G> A single nucleotide variant Pathogenic rs193922219 GRCh37 Chromosome 15, 48738898: 48738898
38 BRAF NM_004333.4(BRAF): c.1780G> A (p.Asp594Asn) single nucleotide variant Pathogenic/Likely pathogenic rs397516896 GRCh37 Chromosome 7, 140453155: 140453155
39 BRAF NM_004333.4(BRAF): c.1798G> A (p.Val600Met) single nucleotide variant Pathogenic/Likely pathogenic rs121913378 GRCh37 Chromosome 7, 140453137: 140453137
40 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
41 BRAF NM_004333.4(BRAF): c.1790T> A (p.Leu597Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
42 NRAS NM_002524.4(NRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
43 BRAF NM_004333.4(BRAF): c.1785T> G (p.Phe595Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913341 GRCh37 Chromosome 7, 140453150: 140453150
44 BRAF NM_004333.4(BRAF): c.1785T> A (p.Phe595Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913341 GRCh37 Chromosome 7, 140453150: 140453150
45 BRAF NM_004333.4(BRAF): c.1783T> C (p.Phe595Leu) single nucleotide variant Pathogenic/Likely pathogenic rs794729219 GRCh37 Chromosome 7, 140453152: 140453152
46 NRAS NM_002524.4(NRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913237 GRCh38 Chromosome 1, 114716126: 114716126
47 MAP2K1 NM_002755.3(MAP2K1): c.171G> T (p.Lys57Asn) single nucleotide variant Pathogenic/Likely pathogenic rs869025608 GRCh38 Chromosome 15, 66435117: 66435117
48 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
49 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh37 Chromosome 1, 115256528: 115256528
50 BRAF NM_004333.4(BRAF): c.1390G> A (p.Gly464Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913349 GRCh37 Chromosome 7, 140481418: 140481418

Cosmic variations for Melanoma:

9 (show top 50) (show all 226)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM231655 PREX2 skin,back,malignant melanoma,superficial spreading c.2531G>A p.G844D 7
2 COSM231663 PREX2 skin,back,malignant melanoma,superficial spreading c.4165G>A p.E1389K 7
3 COSM1756934 NF1 skin,back,malignant melanoma,nodular c.3028C>T p.Q1010* 7
4 COSM1651647 KIT skin,eye,malignant melanoma,NS c.1459G>A p.G487S 7
5 COSM1137 BRAF skin,back,malignant melanoma,superficial spreading c.1817G>A p.G606E 7
6 COSM1136 BRAF skin,back,malignant melanoma,superficial spreading c.1814G>A p.S605N 7
7 COSM1123 BRAF skin,back,malignant melanoma,nodular c.1784T>C p.F595S 7
8 COSM231656 skin,back,malignant melanoma,superficial spreading c.2531G>A p.G844D 7
9 COSM10656 TP53 skin,NS,malignant melanoma,superficial spreading c.742C>T p.R248W 6
10 COSM10863 TP53 skin,back,malignant melanoma,NS c.833C>T p.P278L 6
11 COSM44026 TP53 skin,NS,malignant melanoma,superficial spreading c.559G>A p.G187S 6
12 COSM43690 TP53 skin,NS,malignant melanoma,superficial spreading c.592G>A p.E198K 6
13 COSM10867 TP53 skin,NS,malignant melanoma,nodular c.797G>A p.G266E 6
14 COSM5610575 RUNX1T1 skin,back,malignant melanoma,NS c.206C>T p.S69F 6
15 COSM5610538 RPTOR skin,back,malignant melanoma,NS c.484G>A p.G162R 6
16 COSM131810 ROR2 skin,back,malignant melanoma,NS c.1172T>C p.V391A 6
17 COSM125734 RAC1 skin,NS,malignant melanoma,nodular c.85C>T p.P29S 6
18 COSM142711 PTPRT skin,back,malignant melanoma,NS c.4372G>A p.E1458K 6
19 COSM142708 PTPRT skin,back,malignant melanoma,NS c.2779G>A p.D927N 6
20 COSM5610410 PTPRK skin,back,malignant melanoma,NS c.3251+2T>A p.? 6
21 COSM5610413 PTPRK skin,back,malignant melanoma,NS c.3894C>T p.I1298I 6
22 COSM142789 PTPRH skin,back,malignant melanoma,NS c.2969C>T p.P990L 6
23 COSM5610296 PTPRD skin,back,malignant melanoma,NS c.3487G>A p.E1163K 6
24 COSM142712 PTPRD skin,back,malignant melanoma,NS c.182G>A p.G61E 6
25 COSM142820 PTPN12 skin,back,malignant melanoma,NS c.2314C>T p.P772S 6
26 COSM142819 PTPN12 skin,back,malignant melanoma,NS c.1448C>T p.S483L 6
27 COSM5610076 PTK2B skin,back,malignant melanoma,NS c.596C>T p.S199F 6
28 COSM5142 PTEN skin,NS,malignant melanoma,superficial spreading c.112C>T p.P38S 6
29 COSM5111 PTEN skin,lower leg,malignant melanoma,superficial spreading c.737C>T p.P246L 6
30 COSM5119 PTEN skin,NS,malignant melanoma,nodular c.730C>T p.P244S 6
31 COSM231627 PREX2 skin,lower leg,malignant melanoma,superficial spreading c.34G>T p.E12* 6
32 COSM231647 PREX2 skin,NS,malignant melanoma,nodular c.1994C>T p.P665L 6
33 COSM231666 PREX2 skin,NS,malignant melanoma,nodular c.4669C>T p.R1557C 6
34 COSM231662 PREX2 skin,upper leg,malignant melanoma,nodular c.4127C>T p.A1376V 6
35 COSM231661 PREX2 skin,back,malignant melanoma,NS c.4066G>A p.E1356K 6
36 COSM231665 PREX2 skin,lower leg,malignant melanoma,superficial spreading c.4646C>T p.A1549V 6
37 COSM231651 PREX2 skin,upper leg,malignant melanoma,nodular c.2323C>T p.P775S 6
38 COSM231631 PREX2 skin,NS,malignant melanoma,nodular c.468G>A p.K156K 6
39 COSM5609955 PLCG1 skin,back,malignant melanoma,NS c.1161G>A p.K387K 6
40 COSM760 PIK3CA skin,back,malignant melanoma,NS c.1624G>A p.E542K 6
41 COSM4713314 PDGFRB skin,back,malignant melanoma,NS c.3058G>A p.D1020N 6
42 COSM1294479 PAK3 skin,back,malignant melanoma,NS c.525T>A p.D175E 6
43 COSM5609727 PAK3 skin,back,malignant melanoma,NS c.1015T>C p.W339R 6
44 COSM131783 NTRK1 skin,back,malignant melanoma,NS c.1137G>A p.M379I 6
45 COSM580 NRAS skin,NS,malignant melanoma,nodular c.181C>A p.Q61K 6
46 COSM583 NRAS skin,NS,malignant melanoma,nodular c.182A>T p.Q61L 6
47 COSM577 NRAS skin,NS,malignant melanoma,superficial spreading c.52G>A p.A18T 6
48 COSM585 NRAS skin,back,malignant melanoma,NS c.183A>T p.Q61H 6
49 COSM584 NRAS skin,NS,malignant melanoma,nodular c.182A>G p.Q61R 6
50 COSM561 NRAS skin,NS,malignant melanoma,nodular c.34G>C p.G12R 6

Copy number variations for Melanoma from CNVD:

7 (show top 50) (show all 1973)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13791 1 1 46500000 Insertion Melanoma
2 13897 1 1007060 1041599 Amplification C1orf159 Melanoma
3 14968 1 111600000 148000000 Deletion Melanoma
4 15008 1 111800000 116100000 Gain NRAS Melanoma
5 15387 1 115048600 115061038 Gain NRAS Melanoma
6 18715 1 147200000 149200000 Ampfication SETDB1 Melanoma
7 20086 1 15300000 247249719 Insertion Melanoma
8 21281 7 92072170 92303813 Gain CDK6 Malignant melanoma
9 24543 1 182188599 196365692 Amplification ASPM Melanoma
10 24544 1 182188599 196365692 Amplification ATP6V1G3 Melanoma
11 24545 1 182188599 196365692 Amplification B3GALT2 Melanoma
12 24546 1 182188599 196365692 Amplification C1orf27 Melanoma
13 24547 1 182188599 196365692 Amplification C1orf53 Melanoma
14 24548 1 182188599 196365692 Amplification C1orf99 Melanoma
15 24549 1 182188599 196365692 Amplification CDC73 Melanoma
16 24550 1 182188599 196365692 Amplification CFH Melanoma
17 24551 1 182188599 196365692 Amplification CFHR1 Melanoma
18 24552 1 182188599 196365692 Amplification CFHR2 Melanoma
19 24553 1 182188599 196365692 Amplification CFHR3 Melanoma
20 24554 1 182188599 196365692 Amplification CFHR4 Melanoma
21 24555 1 182188599 196365692 Amplification CFHR5 Melanoma
22 24556 1 182188599 196365692 Amplification CRB1 Melanoma
23 24557 1 182188599 196365692 Amplification DENND1B Melanoma
24 24558 1 182188599 196365692 Amplification F13B Melanoma
25 24559 1 182188599 196365692 Amplification FAM5C Melanoma
26 24560 1 182188599 196365692 Amplification GLRX2 Melanoma
27 24561 1 182188599 196365692 Amplification HMCN1 Melanoma
28 24562 1 182188599 196365692 Amplification KCNT2 Melanoma
29 24563 1 182188599 196365692 Amplification LHX9 Melanoma
30 24564 1 182188599 196365692 Amplification NEK7 Melanoma
31 24565 1 182188599 196365692 Amplification OCLM Melanoma
32 24566 1 182188599 196365692 Amplification PDC Melanoma
33 24567 1 182188599 196365692 Amplification PLA2G4A Melanoma
34 24568 1 182188599 196365692 Amplification PRG4 Melanoma
35 24569 1 182188599 196365692 Amplification PTGS2 Melanoma
36 24570 1 182188599 196365692 Amplification PTPRC Melanoma
37 24571 1 182188599 196365692 Amplification RGS1 Melanoma
38 24572 1 182188599 196365692 Amplification RGS13 Melanoma
39 24573 1 182188599 196365692 Amplification RGS18 Melanoma
40 24574 1 182188599 196365692 Amplification RGS2 Melanoma
41 24575 1 182188599 196365692 Amplification RGS21 Melanoma
42 24576 1 182188599 196365692 Amplification TPR Melanoma
43 24577 1 182188599 196365692 Amplification TROVE2 Melanoma
44 24578 1 182188599 196365692 Amplification UCHL5 Melanoma
45 24579 1 182188599 196365692 Amplification ZBTB41 Melanoma
46 26238 1 198304656 198310281 Deletion Melanoma
47 29172 1 228366540 228914590 LOH Melanoma
48 29295 1 2300000 46500000 Insertion Melanoma
49 29296 1 2300000 46500000 Insertion Melanoma
50 30306 1 241700000 247249719 Insertion Melanoma

Expression for Melanoma

Search GEO for disease gene expression data for Melanoma.

Pathways for Melanoma

Pathways related to Melanoma according to KEGG:

37
id Name Kegg Source Accession
1 Melanoma hsa05218

Pathways related to Melanoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.38 BRAF CDK4 CDKN2A
2 11.16 BRAF CDKN2A IL24
3 10.66 BRAF CDK4 CDKN2A

GO Terms for Melanoma

Biological processes related to Melanoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cellular senescence GO:0090398 9.16 CDKN2A MAGEA2
2 positive regulation of ubiquitin-protein transferase activity GO:0051443 8.96 MAGEA2 MAGEC2
3 cellular protein catabolic process GO:0044257 8.62 MAGEA2 MAGEC2

Molecular functions related to Melanoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.53 BRAF CDK4 CDKN2A GPNMB IL24 MAGEA1

Sources for Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....